Related Experiment Video
Updated: Jan 5, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Treatment of Malignant Peritoneal Mesothelioma
Abstract:
Malignant mesothelioma is a highly malignant disease that most often occurs in the pleura of the thoracic cavity, followed by the peritoneum, pericardium, or tinea vaginalis testis. Malignant peritoneal mesothelioma (MPM) accounts for 10-15% of all mesotheliomas. The most significant risk factor for MPM is exposure to asbestos. There is no specific symptomatology, and imaging (computed tomography) and histopathology are crucial for diagnosis. There are no generally accepted guidelines for radical treatment of MPM. Previously, the prognosis of MPM patients was poor, with survival of up to 1 year. However, median survival of patients who are suitable candidates for radical therapy is currently 3-5 years. A combination of cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy (HIPEC) is recommended in selected patients, while chemotherapy alone has insufficient efficacy. Systemic chemotherapy remains the only treatment option for patients who are unsuitable for CRS and HIPEC. In selected patients scheduled for or currently undergoing CRS and HIPEC, surgery may be performed in combination with systemic chemotherapy in the neoadjuvant or adjuvant setting; however, the benefit is unclear. There are no recommendations for follow-up of MPM patients after radical surgery. Existing guidelines for the pleural form (e.g., those issued by the European Society for Medical Oncology) do not specify the frequency or method of investigation. In the absence of specific serum markers, only CA 125 and mesothelin are generally available. Imaging methods include ultrasonography, computed tomography, and magnetic resonance imaging.
Insights
Malignant peritoneal mesothelioma (MPM) is a rare cancer linked to asbestos. Cytoreductive surgery with hyperthermic perioperative chemotherapy offers improved survival for select patients, though treatment guidelines are still evolving.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Malignant mesothelioma, particularly malignant peritoneal mesothelioma (MPM), is a rare and aggressive cancer.
- Asbestos exposure is the primary risk factor for MPM, which accounts for 10-15% of all mesotheliomas.
- Diagnosis relies on imaging like CT scans and histopathology, as symptoms are non-specific.
Purpose of the Study:
- To review the current understanding of malignant peritoneal mesothelioma (MPM) diagnosis and treatment.
- To highlight the evolving treatment landscape, including cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy (HIPEC).
- To address the lack of established follow-up guidelines post-radical surgery for MPM.
Main Methods:
- Review of existing literature and clinical guidelines for MPM.
- Analysis of diagnostic modalities including imaging (CT, MRI, ultrasound) and histopathology.
- Evaluation of treatment strategies: CRS + HIPEC, systemic chemotherapy, and neoadjuvant/adjuvant chemotherapy.
Main Results:
- Median survival for MPM patients suitable for radical therapy has improved to 3-5 years with CRS + HIPEC, compared to 1 year previously.
- Chemotherapy alone is less effective, and its benefit in combination with CRS + HIPEC remains unclear.
- Current follow-up recommendations for MPM post-surgery are lacking, with limited serum markers (CA 125, mesothelin) and standard imaging techniques used.
Conclusions:
- Cytoreductive surgery combined with hyperthermic perioperative chemotherapy represents the current standard of care for select MPM patients, offering improved survival.
- Systemic chemotherapy is the primary option for patients not eligible for CRS + HIPEC.
- Further research is needed to establish definitive treatment protocols and follow-up strategies for MPM.
